Scancell to List on Nasdaq via Reverse Merger with Neuphoria, Securing Funding for Phase 3 iSCIB1+ Trial
Nasdaq Listing via Reverse Merger and Entry into the U.S. Capital Market
Scancell, a UK-based immuno-oncology company, has officially formalized a reverse merger with Neuphoria Therapeutics, a Nasdaq-listed company, through a stock exchange. This merger allows Scancell to be listed on the Nasdaq under the ticker symbol 'SCLT,' providing access to global capital, while also maintaining its existing listing on the London AIM market. Upon completion of the merger, Scancell shareholders will hold 85.5% and Neuphoria shareholders will hold 14.5%, with Neuphoria shareholders receiving a contingent value right (CVR). This is considered a representative strategic restructuring case where a biotech company seeks a breakthrough in fundraising.
Neuphoria's Clinical Failure and Survival Through a Shell Company
Neuphoria was formerly Bionomics, which changed its name and was listed on the U.S. Nasdaq (NEUP) in December 2024. However, its key candidate, BNC210 (soclenicant), failed to achieve the primary endpoint in the Phase 3 trial (AFFIRM-1) for social anxiety disorder (SAD) in October 2025, leading to the complete discontinuation of pipeline development. Ultimately, to overcome financial difficulties, it accepted Scancell's merger proposal, deciding to protect shareholder value. This merger exemplifies the reality of the biotech industry, where a biotech company facing clinical failure provides a Nasdaq shell to survive.
Clinical Roadmap for iSCIB1+, a Next-Generation Melanoma Vaccine
Scancell's iSCIB1+ is a next-generation DNA cancer vaccine that targets dendritic cells and delivers gp100 and TRP-2 epitopes. It is a candidate with significantly expanded versatility compared to the existing SCIB1 vaccine, extending the range of patient HLA genotypes to approximately 80%. Scancell has received IND approval and Fast Track designation from the U.S. FDA and plans to initiate a global Phase 3 registrational trial in the second half of 2026. If approved, this vaccine is expected to redefine the standard of care for melanoma treatment in combination with existing immune checkpoint inhibitors such as Opdivo (nivolumab) and Yervoy (ipilimumab).
Securing $89 Million in Funding and Financial Stability
This merger not only facilitates a Nasdaq listing but also secures a significant financing package totaling $89 million, representing a major financial achievement. Specifically, this includes a $39.1 million private placement, a $15 million UK offering, and $25 million in debt financing from a BlackRock-managed fund. The secured funds provide a solid foundation to complete the costly Phase 3 trial for iSCIB1+ and extend the cash runway to 2029. This reduces the risk of stock dilution during the clinical pipeline development process, which is a significant positive for investors.
Competition in the Advanced Melanoma Treatment Market and Commercialization Prospects
The advanced melanoma treatment market is a high-value area, projected to grow from $4.5 billion in 2026 to $6.37 billion in 2030. While standard treatments include immune checkpoint inhibitors such as Opdivo and Keytruda, there is a high demand for new combinations to overcome resistance. Scancell's iSCIB1+ has demonstrated remarkable efficacy in the Phase 2 trial (SCOPE), with a 20-month progression-free survival (PFS) rate of 77%. If the Phase 3 trial demonstrates superior combination data, it is expected to strengthen its position for a potential large licensing deal with a global pharmaceutical company.
This reverse merger and the $89 million in funding secured provide investors with strong confidence, as it ensures that Scancell has the financial resources to support the global Phase 3 trial for iSCIB1+ starting in the second half of 2026 and guarantees financial stability through 2029. In particular, in the advanced melanoma treatment market, which is expected to expand from $4.5 billion in 2026 to $6.37 billion in 2030, this provides the momentum to directly compete with or combine with the existing standard treatment, BMS's Opdivo and Yervoy combination therapy. From the perspective of researchers and developers, this provides a medium- to long-term opportunity to validate the efficacy of a DNA vaccine platform that targets dendritic cells and increases the patient HLA response rate to 80% through a large-scale Phase 3 trial. In the broader biotech industry, this represents a benchmark model for capital market restructuring, where Scancell successfully acquired Neuphoria's shell company, which was facing limitations on the Nasdaq (NEUP) due to clinical failure, and successfully listed on the Nasdaq (SCLT).
Source: FierceBiotech (rss)